Literature DB >> 12370758

Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome.

Ken-ichi Kiyomiya1, Jun Satoh, Hiroshi Horie, Masaru Kurebe, Hiroshi Nakagawa, Saburou Matsuo.   

Abstract

4'-O-tetrahydropyranyladriamycin (THP) showed an approximately 10-fold greater inhibitory effect on DNA synthesis in L1210 mouse leukemia cells than adriamycin (ADM). The intracellular transfer rate and nuclear accumulation of THP were approximately 5-fold higher than those of ADM. The intensity of in vitro inhibition of topoisomerase II activity by ADM was almost the same as that by THP. There were no significant differences between the uptake of either of these agents by the isolated nuclei of L1210 cells. The nuclear uptake of both agents in the presence of the cytosolic fraction of L1210 cells consisted of both simple diffusion and carrier-mediated components, and the carrier-mediated component of THP was approximately 2-fold higher than that of ADM. THP showed approximately 5-fold higher affinity to the proteasome than ADM, and interfered with ADM binding in a competitive manner. These results suggest that the binding affinity of these anticancer agents to the proteasome is an important factor in their transport to the nucleus and determines their specificity of action for the nuclear DNA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370758

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

2.  Simultaneous EGFP and tag labeling of the β7 subunit for live imaging and affinity purification of functional human proteasomes.

Authors:  Valentina A Kulichkova; Tatiana O Artamonova; Julia J Zaykova; Julia B Ermolaeva; Mikhail A Khodorkovskii; Nikolai A Barlev; Alexey N Tomilin; Anna S Tsimokha
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.695

3.  Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligases.

Authors:  Marcia Gracindo da Silva; Elisabete Mattos; Juliana Camacho-Pereira; Tatiana Domitrovic; Antonio Galina; Mauro W Costa; Eleonora Kurtenbach
Journal:  Exp Clin Cardiol       Date:  2012-09

Review 4.  Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.

Authors:  Mark J Ranek; Xuejun Wang
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

5.  A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

Authors:  Jinbao Liu; Hanqiao Zheng; Mingxin Tang; Youn-Chul Ryu; Xuejun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-31       Impact factor: 4.733

6.  Anthracyclines, proteasome activity and multi-drug-resistance.

Authors:  Mirela R Fekete; William H McBride; Frank Pajonk
Journal:  BMC Cancer       Date:  2005-09-13       Impact factor: 4.430

7.  DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity.

Authors:  Tatiana N Moiseeva; Andrew Bottrill; Gerry Melino; Nickolai A Barlev
Journal:  Oncotarget       Date:  2013-09

8.  Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

Authors:  Yan Xu; Jin Wang; Wanggang Zhang; Jie Liu; Xingmei Cao; Aili He; Yinxia Chen; Liufang Gu; Bo Lei; Pengyu Zhang; Xiaorong Ma
Journal:  Med Sci Monit       Date:  2016-11-11

9.  Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer.

Authors:  Qiongli Su; Ting Tao; Lei Tang; Jun Deng; Kwame Oteng Darko; Sichun Zhou; Mei Peng; Shanping He; Qing Zeng; Alex F Chen; Xiaoping Yang
Journal:  J Cell Mol Med       Date:  2018-03-07       Impact factor: 5.310

10.  Bioorthogonal release of anticancer drugs via gold-triggered 2-alkynylbenzamide cyclization.

Authors:  Kenward Vong; Tomoya Yamamoto; Tsung-Che Chang; Katsunori Tanaka
Journal:  Chem Sci       Date:  2020-09-02       Impact factor: 9.825

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.